Zacks: Analysts Anticipate Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Will Post Quarterly Sales of $2.25 Million

Equities research analysts expect that Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS – Get Rating) will announce sales of $2.25 million for the current fiscal quarter, according to Zacks. Five analysts have provided estimates for Marinus Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $2.00 million and the highest estimate coming in at $2.63 million. Marinus Pharmaceuticals posted sales of $1.91 million during the same quarter last year, which suggests a positive year-over-year growth rate of 17.8%. The company is expected to announce its next quarterly earnings report on Monday, January 1st.

According to Zacks, analysts expect that Marinus Pharmaceuticals will report full year sales of $44.83 million for the current financial year, with estimates ranging from $22.64 million to $127.70 million. For the next year, analysts anticipate that the business will post sales of $29.63 million, with estimates ranging from $16.90 million to $49.18 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side analysts that cover Marinus Pharmaceuticals.

Marinus Pharmaceuticals (NASDAQ:MRNS – Get Rating) last released its quarterly earnings data on Monday, March 21st. The biopharmaceutical company reported ($0.77) EPS for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.04. The company had revenue of $1.52 million during the quarter, compared to the consensus estimate of $2.64 million. Marinus Pharmaceuticals had a negative net margin of 328.21% and a negative return on equity of 145.46%. During the same quarter in the prior year, the firm earned ($0.55) EPS.

A number of research firms have commented on MRNS. Cantor Fitzgerald increased their price objective on shares of Marinus Pharmaceuticals from $25.00 to $28.00 in a report on Wednesday, April 20th. Truist Financial increased their price objective on shares of Marinus Pharmaceuticals from $35.00 to $50.00 and gave the company a “buy” rating in a report on Tuesday, March 22nd. Zacks Investment Research upgraded shares of Marinus Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, February 26th. SVB Leerink cut their price target on shares of Marinus Pharmaceuticals from $30.00 to $27.00 and set an “outperform” rating for the company in a report on Tuesday, March 22nd. Finally, StockNews.com started coverage on shares of Marinus Pharmaceuticals in a report on Thursday, March 31st. They set a “sell” rating for the company. One analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $29.63.

MRNS stock opened at $5.32 on Monday. The company has a market cap of $197.58 million, a price-to-earnings ratio of -2.15 and a beta of 1.49. The company has a current ratio of 6.91, a quick ratio of 3.25 and a debt-to-equity ratio of 1.94. Marinus Pharmaceuticals has a 12 month low of $4.19 and a 12 month high of $19.83. The firm has a 50-day moving average of $7.70 and a two-hundred day moving average of $9.67.

Several large investors have recently bought and sold shares of MRNS. Suvretta Capital Management LLC boosted its position in shares of Marinus Pharmaceuticals by 20.1% during the 4th quarter. Suvretta Capital Management LLC now owns 2,638,775 shares of the biopharmaceutical company’s stock worth $31,349,000 after purchasing an additional 441,349 shares during the period. Jefferies Group LLC boosted its position in shares of Marinus Pharmaceuticals by 2,774.8% during the 3rd quarter. Jefferies Group LLC now owns 439,764 shares of the biopharmaceutical company’s stock worth $5,005,000 after purchasing an additional 424,467 shares during the period. Bleichroeder LP boosted its position in shares of Marinus Pharmaceuticals by 24.5% during the 1st quarter. Bleichroeder LP now owns 1,322,463 shares of the biopharmaceutical company’s stock worth $12,365,000 after purchasing an additional 259,963 shares during the period. GSA Capital Partners LLP purchased a new position in shares of Marinus Pharmaceuticals during the 3rd quarter worth approximately $1,461,000. Finally, Granite Point Capital Management L.P. boosted its position in shares of Marinus Pharmaceuticals by 12.6% during the 1st quarter. Granite Point Capital Management L.P. now owns 472,056 shares of the biopharmaceutical company’s stock worth $4,414,000 after purchasing an additional 52,732 shares during the period. 80.89% of the stock is owned by hedge funds and other institutional investors.

Marinus Pharmaceuticals Company Profile (Get Rating)

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY, an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.

Recommended Stories